Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML

• Published in: Leukemia research Vol. 144; p. 107547
• Main Authors: Wu, Shuangshuang, Liu, Fangbing, Gai, Yuqing, Carter, Jenna, Edwards, Holly, Hüttemann, Maik, Wang, Guan, Li, Chunhuai, Taub, Jeffrey W., Wang, Yue, Ge, Yubin
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2024
• Subjects: Acute myeloid leukemia; Bcl-2; FLT3-ITD; MRX-2843; Venetoclax; AML; Bcl-2; s.e.m; FLT3; CI; OXPHOS; MRX-2843; AraC; TKD; PBMCs; FITC; CMST; FLT3-ITD; PI; NTC; RFP; Acute myeloid leukemia; CFUs; VEN; Venetoclax; OCR
• ISSN: 0145-2126; 1873-5835; 1873-5835
• DOI: 10.1016/j.leukres.2024.107547

FMS-like tyrosine kinase 3 (FLT3) mutations occur in approximately one third of acute myeloid leukemia (AML) patients. FLT3-Internal tandem duplication (FLT3-ITD) mutations are the most common FLT3 mutations and are associated with a poor prognosis. Gilteritinib is a FLT3 inhibitor that is US FDA approved for treating adult patients with relapsed/refractory AML and a FLT3 mutation. While gilteritinib monotherapy has improved patient outcome, few patients achieve durable responses. Combining gilteritinib with venetoclax (VEN) appears to make further improvements, though early results suggest that patients with prior exposure to VEN fair much worse than those without prior exposure. MRX-2843 is a promising inhibitor of FLT3 and MERTK. We recently demonstrated that MRX-2843 is equally potent as gilteritinib in FLT3-ITD AML cell lines in vitro and primary patient samples ex vivo. In this study, we investigated the combination of VEN and MRX-2843 against FLT3-ITD AML cells. We found that VEN synergistically enhances cell death induced by MRX-2843 in FLT3-mutated AML cell lines and primary patient samples. Importantly, we found that VEN synergistically enhances cell death induced by MRX-2843 in FLT3-ITD AML cells with acquired resistance to cytarabine (AraC) or VEN+AraC. VEN and MRX-2843 significantly reduce colony-forming capacity of FLT3-ITD primary AML cells. Mechanistic studies show that MRX-2843 decreases Mcl-1 and c-Myc protein levels via transcriptional regulation and combined MRX-2843 and VEN significantly decreases oxidative phosphorylation in FLT3-ITD AML cells. Our findings highlight a promising combination therapy against FLT3-ITD AML, supporting further in vitro and in vivo testing. •Venetoclax synergistically enhances cell death induced by MRX-2843 in FLT3-ITD AML.•Venetoclax+MRX-2843 induces cell death in AraC resistant FLT3-ITD AML cells.•MRX-2843 decreases Mcl-1 and c-Myc protein levels via transcriptional regulation.•Mcl-1 and c-Myc play important roles in the synergy of MRX-2843 and venetoclax.•MRX-2843 + venetoclax significantly decreases oxidative phosphorylation.